TREATMENT OF ASPIRIN RESISTANCE WITH BETAINE AND/OR BETAINE ENRICHED MOLASSES

• US 20100292327A1
• Filed: 05/19/2010
• Published: 11/18/2010
• Est. Priority Date: 11/21/2007
• Status: Abandoned Application

• Current Assignee: Jallal Messadek
• Original Assignee: Jallal Messadek
• Inventors: Messadek, Jallal
• Application Number:
  US12/783,377
• Publication Number:
  US 20100292327A1
• Time in Patent Office: Days
• US Class Current: 514/551
• CPC Class Codes: A23L 29/30 containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin products from apiculture A23L21/20; artificial sweetening agents A23L27/30
• CPC Class Codes: A23L 33/10 using additives addition of substantially indigestible substances A23L33/21
• CPC Class Codes: A23L 33/125 containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates indigestible substances A23L33/21
• CPC Class Codes: A23L 5/00 Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/326 having effect on cardiovascular health
• CPC Class Codes: A23V 2250/302 Betaine, trimethylglycine
• CPC Class Codes: A61K 31/205 Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Use of glycine betaine as therapeutically active ingredient for the preparation of a medicament and/or a nutritional product and/or a dietary supplement for treating human resistant to a compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof, who suffers from a disease requiring the administration of a compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof, or who is at risk of suffering of said disease, whereby the medicament comprises an effective amount of glycine betaine for decreasing by at least 10%, advantageously at least 20% the resistance of said patient to said compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof

Claims

1. A method of treating a human having a condition or being at risk for a condition selected from the group consisting of:

(a) high levels of urinary and/or blood levels of 11-dehydro thromboxane B2 after being administered one or more antiplatelet compounds selected from the group consisting of aspirin, aspirin derivatives and combinations thereof;

(b) high levels of platelet and/or blood aggregation after being administered one or more antiplatelet compounds selected from the group consisting of aspirin, aspirin derivatives and combinations thereof;

(c) aspirin resistance;

(d) poor response to aspirin;

(e) resistance to at least two compounds selected from the group consisting of aspirin, clopidogrel, thienopyridines, and combinations thereof;

(f) resistance to aspirin, clopidogrel, or thienopyridines, who suffers or who is at risk of suffering of cardiovascular diseases, cerebrovascular diseases, or combinations thereof, while being treated by one or more of said compounds;

(g) cardiovascular diseases, cerebrovascular diseases, or combinations thereof who is aspirin resistant;

(h) thromboembolic disorders, ischemic disorders, or combinations thereof, who is resistant to aspirin, clopidogrel, or thienopyridines;

(i) thromboembolic disorders, in which an increase in thromboxane formation cannot be prevented by conventional dose rates of aspirin;

(j) reperfusion damage/ischemia, myocardial infarction, thrombolysis, tumours, stroke or balloon dilatation; and

(k) a disease requiring the administration of aspirin, in which an increase in thromboxane formation cannot be prevented by conventional dose rates of aspirin, said method comprising;

administering to said human a therapeutically effective amount of a betaine, a betaine enriched molasses, or a combination thereof.

2. The method of claim 1, wherein said condition is (a), and wherein the urine level of 11-dehydro thromboxane B2 is greater than 15 ng/mmol creatinine.

3. The method of claim 1, wherein said condition is (b), and wherein blood aggregation is realised using as an agonist arachidonic acid, collagen, or both.

4. The method of claim 3, wherein the threshold concentration for the agonist is 1 μ

g/ml for collagen and 0.5 mM for arachidonic acid.

5. The method of claim 1, wherein said condition is (b), and wherein the levels of platelet or blood aggregation of said human are inferior by less than 20% compared to the levels of platelet or blood aggregation of said human prior to being administered one or more antiplatelet compounds selected from the group consisting of aspirin, aspirin derivatives and combinations thereof.

6. The method of claim 1, wherein said condition is (c), and wherein said aspirin resistance is decreased by at least 10%.

7. The method of claim 1, wherein said condition is (a), and wherein said high levels of urinary and/or blood levels of 11-dehydro thromboxane B2 are decreased by at least 10%.

8. The method of claim 1, wherein said betaine comprises an effective amount of glycine betaine for rendering said patient substantially no more resistant to aspirin, clopidogrel and thienopyridines.

9. The method of claim 1, wherein said condition is (k), said betaine is glycine betaine or glycine betaine enriched molasses, and wherein said aspirin resistance is decreased by at least 10%

10. A betaine enriched molasses comprising between 10% and 95% of betaine on a dry matter basis for the fabrication of a nutritional product.

11. The betaine enriched molasses according to claim 10, said nutritional product being effective for achieving one or more health and/or therapeutical purpose selected from the group consisting of:

improve athletic performance, improve haemostasis, sustain healthy haemostasis, favour healthy haemostasis, improve favour haemostasis, sustain haemostasis, ameliorate haemostasis, reinforce haemostasis, improve cardiovascular function, sustain healthy cardiovascular function, favour healthy cardiovascular function, favour cardiovascular function, sustain cardiovascular function, ameliorate cardiovascular function, reinforce cardiovascular function, improve blood circulation, favour healthy blood circulation, favour blood circulation, sustain healthy blood circulation, sustain blood circulation, ameliorate blood circulation, reinforce blood circulation, improve blood microcirculation, favour blood microcirculation, sustain healthy blood microcirculation, sustain blood microcirculation, ameliorate blood microcirculation, reinforce blood microcirculation, improve platelet function, improve healthy platelet function, favour healthy platelet function, favour platelet function, sustain healthy platelet function, sustain platelet function, ameliorate platelet function, pacify platelet, favour platelet pacification, sustain platelet pacification, reinforce platelet pacification, reinforce platelet function, favour healthy sensitivity to aspirin, improve sensitivity to aspirin, favour sensitivity to aspirin, sustain healthy sensitivity to aspirin, sustain sensitivity to aspirin, ameliorate sensitivity to aspirin, reinforce sensitivity to aspirin, favour healthy sensitivity to clopidogrel, improve sensitivity to clopidogrel, favour sensitivity to clopidogrel, sustain healthy sensitivity to clopidogrel, improve sensitivity to clopidogrel, sustain sensitivity to clopidogrel, ameliorate sensitivity to clopidogrel, reinforce sensitivity to clopidogrel, favour healthy sensitivity to thienopyridines, improve sensitivity to thienopyridines, favour sensitivity to thienopyridines, sustain healthy sensitivity to thienopyridines, improve sensitivity to thienopyridines, sustain sensitivity to thienopyridines, ameliorate sensitivity to thienopyridines, reinforce sensitivity to thienopyridines, reduce the risk of aspirin resistance, reduce the risk of clopidogrel resistance, reduce the risk of thienopyridines resistance, ameliorate aspirin resistance, ameliorate clopidogrel resistance, ameliorate thienopyridines resistance, reduce the risk of diabetes, ameliorate diabetes, improve glycemia in diabetic states, ameliorate glycemia in diabetic states, ameliorate insulin resistance in diabetic states, favour healthy insulin sensitivity, improve insulin sensitivity, favour insulin sensitivity, sustain healthy insulin sensitivity, sustain insulin sensitivity, ameliorate insulin sensitivity, reinforce insulin sensitivity, favour healthy glycemia, favour normal glycemia, sustain healthy glycemia, sustain normal glycemia, ameliorate glycemia, reinforce healthy glycemia, reduce the risk of high glycemia, improve glucose utilisation, ameliorate glucose utilisation, ameliorate glucose utilisation by the body, favour healthy legs circulation, favour legs circulation, sustain healthy legs circulation, improve legs circulation, sustain legs circulation, ameliorate legs circulation, reinforce legs circulation, favour healthy erectile function, improve erectile function, favour erectile function, sustain healthy erectile function, sustain erectile function, ameliorate erectile function, reinforce erectile function, relieve the haemorrhoids crisis, relieve heavy legs, reduce the risk of inflammation, reduce the risk of cancer, reduce the risk of Alzheimer Disease, ameliorate vision; and

the mixtures of such health purposes.

12. The betaine enriched molasses according to claim 10, wherein said molasses comprises between 20% and 80% of betaine on a dry matter basis.

13. The betaine enriched molasses according to claim 10, wherein said nutritional product is effective for treating or preventing aspirin resistance in a patient in need.

14. The betaine enriched molasses according to claim 10, wherein said nutritional product is effective for treating or preventing clopidogrel resistance and/or thienopyridines resistance in a patient in need.

15. A betaine enriched molasses according to claim 10, further comprising 5 to 65% sugar, 1 to 40% essential amino acids, 1 to 30% nitrates, and 1 to 40% organic acids.

16. A betaine enriched molasses according to claim 15, wherein said essential amino acids are selected from the group consisting of one or more lysine, methionine, cystine, tryptophan, threonine and theirs mixtures.

17. A betaine enriched molasses according to claim 15, wherein said organic acids are selected from the group consisting of one or more lactic acid, malic acid, acetic acid, oxalic acid, glutammic acid, citric acid, succinic acid and theirs mixtures.

18. A betaine enriched molasses according to claim 10, wherein said nutritional product is sealed in a unit dosage form which is provided with a moisture barrier property defined by an increase of weight of the compositions of less than 1% after storage of the unit dosage form in scaled condition in an environment with a temperature of 38°

C. and a relative humidity of 90% during 30 days.

19. A betaine enriched molasses according to claim 18, wherein the unit dosage form is selected from the group consisting of sachets, pouches, blisters and bags, wherein the pharmaceutical unit dosage form is provided with moisture barrier property defined by an MVTR value inferior to 0.2 g/m² at a temperature of 38°

C. and at 90% relative humidity during 24 hours.

20. A betaine enriched molasses according to claim 10, wherein said nutritional product is in an oral dosage form selected from the group consisting of drop pills, spray solution, pellets, pills, granules, gels, capsules, tablets, powders, gel soft capsules, gels soft pills and oral liquids.

21. A process for obtaining a betaine enriched molasses according to claim 10 for the fabrication of a medicament and/or nutritional product comprising:

providing desugarized beet molasses, cane molasses, or a combination thereof; and

subjecting said desugarized molasses to a separation process to yield betaine enriched molasses.

22. The process of claim 21, further comprising submitting said betaine enriched molasses to one or more drying processes selected from the group consisting of drying processes, spray-drying, tumble-drying, lyophilisation processes, freeze-drying processes, and combinations thereof.

23. The process of claim 22, further comprising submitting the dried betaine enriched molasses to one or more of another process selected from the group consisting of powdering, micronizing, grinding, crushing, granulating, and combinations thereof.